



Patient Discharge following Molecular Radiotherapy

September 23, **2026** | Valencia, Spain

EBAMP APP00380 14 points

Course Description

This training programme will provide guidance on patient release following radioligand therapy (RLT) with I-131 and Lu-177. Participants will review the regulatory framework (IAEA GSR Part 3, EU BSSD 2013/59/Euratom), measurement principles, and internal dosimetry models required for discharge decisions.

The course will cover RLT workflows, operational quantities and detector selection, international and national legal requirements, and patient-specific dosimetry using SPECT/PET quantification. Mathematical derivation of release criteria based on dose constraints to third parties will be presented. The programme will address regulatory differences across EU Member States and risk communication strategies for patients and caregivers.

Practical sessions will demonstrate calculation methods for I-131 thyroid therapy and Lu-177 PSMA therapy, including exposure scenarios involving family members, caregivers, and the general public. Environmental considerations will include liquid waste management, hospital effluent models, and decay-storage requirements for regulatory compliance.

Learning Objectives

By the end of this course, participants will be able to:

- Explain the clinical workflow of molecular and radioligand therapy and how radionuclide properties and biokinetics determine radiation protection requirements and patient release conditions.
- Apply appropriate measurement principles and instruments for patient release monitoring and interpret results in mixed beta-gamma radiation fields.
- Interpret the main international and European regulatory frameworks for patient discharge and understand the impact of differing national implementations.
- Estimate residual patient activity and potential doses to contacts using simplified and patient-specific internal dosimetry models.
- Apply discharge criteria and release formulae for typical exposure scenarios and formulate effective patient instructions and waste-management measures.

Organize



Welcome nation



6th ECMP 2026

European Congress of Medical Physics

23-26 September 2026 | Valencia | Spain



Faculty

- » **Stephane Chauvie** | Medical Physics Department S. Croce Hospital, Cuneo, Italy
- » **Jaroslav Ptacek** | Department of Medical Physics and Radiation Protection, University Hospital Olomouc, Olomouc, Czechia
- » **Jose Antonio Terrón** | Department of Medical Physics, Hospital Universitario Virgen Macarena, Seville, Spain
- » **Marleen Vandecapelle** | Federal Agency for Nuclear Control, Brussels, Belgium
- » **Jens Kurth** | Department of Nuclear Medicine, Rostock University Medical Center, Rostock, Germany
- » **Lara Struelens** | SCK-CEN, Belgian Nuclear Research Centre, Mol, Belgium

Timetable

	TITLE	LECTURE
9.00–12.15	COURSE PRESENTATION	Jaroslav Ptacek
	OVERVIEW AND WORKFLOW OF RADIOLIGAND THERAPY (RLT)	Stephane Chauvie, Jaroslav Ptacek
	MEASUREMENT PRINCIPLES AND UNITS	Jose Antonio Terrón
	INTERNATIONAL AND EUROPEAN LEGAL FRAMEWORK	Marleen Vandecapelle
	INTERNAL DOSIMETRY	Jens Kurth
12.15–13.15	LUNCH BREAK – AVAILABLE AT PARTICIPANTS EXPENSE IN THE CONGRESS VENUE	
13:15–14.15	PATIENT DISCHARGE CRITERIA AND RELEASE FORMULAE	Lara Struelens
14.15–14.45	PATIENT INSTRUCTIONS AND INFORMATION	Stephane Chauvie, Jaroslav Ptacek
14.45–15.15	COFFEE BREAK – AVAILABLE AT PARTICIPANTS EXPENSE IN THE CONGRESS VENUE	
15.15–15.45	PRACTICAL EXAMPLES	Stephane Chauvie, Jaroslav Ptacek
15.45–16.45	ENVIRONMENTAL CONSIDERATIONS AND LIQUID WASTE MANAGEMENT	Jose Antonio Terrón

Further information

	Course language	English
	Level	MPE - Level 8
	Maximum no. of participants	80
	Duration	23 rd September 2026
	Study load	6 hours of lectures and discussions
	CPD Points	EBAMP APP00380 14 points Spanish certification (EVES) - To be confirmed

Organize



Welcome nation

